ArticleBMC infectious diseases2025
Molecular epidemiology and increasing macrolide resistance of Bordetella pertussis isolates in Guangzhou, China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Immunological insights into why pertussis continues to be endemic.Human vaccines & immunotherapeutics · 2026Review
- Global phylogenomics of Bordetella pertussis ST2 reveals regional heterogeneity in China and lineage-specific genome evolution.BMC genomics · 2026Article
- Co-infection with macrolide-resistant and macrolide-susceptibleASM case reports · 2026Article
- Review
- Macrolide-resistantFrontiers in pediatrics · 2026Article
- Revisiting Whooping Cough: Global Drivers and Implications of Pertussis Resurgence in the Acellular Vaccine Era.Vaccines · 2025Review
- A retrospective study on pediatric pertussis: comprehensive evaluation of symptoms, laboratory indicators, and diagnostic efficacy of case definitions.Frontiers in cellular and infection microbiology · 2025Article
- Co-infection in pediatric pertussis during 2023 and 2024 in southern China: pathogen distribution characteristic and influence on manifestation of pertussis.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundPertussis (whooping cough), a highly contagious respiratory disease caused by Bordetella pertussis, has resurged worldwide and requires increased attention. This study aimed to characterize the molecular epidemiology and antimicrobial susceptibility profiles of B. pertussis isolates circulating in Guangzhou, China.
methodsA total of 91 culture-confirmed pertussis cases in Guangzhou between January 2020 and August 2024 were enrolled and studied. B. pertussis isolates (from January 2020 to May 2024) were recovered from 62 cases. All isolates underwent antigenic genotyping and phylogenetic analysis based on whole-genome sequencing. Antimicrobial susceptibility testing using E-test was performed on 12 representative isolates.
resultsThe majority of culture-confirmed cases occurred in children under 1 year of age who were unvaccinated or partially vaccinated. Genotypic analysis revealed a significant shift: only 3 isolates (all from 2022) harbored the ptxP1 allele, while the remaining 59 exhibited ptxP3. Three types of pertactin (prn) allele were identified: prn1 (4.84%, 3/62), prn2 (11.29%, 7/62), prn150 (80.65%, 50/62), and 2 untyped prn allele. By 2024, prn150 became the predominant allele. Phylogenetic analysis revealed distinct branches separating ptxP1 and ptxP3 lineages. E-test results demonstrated that all macrolide-resistant isolates (exhibiting MICs > 256 mg/L for erythromycin, azithromycin, and clarithromycin) carried the A2047G mutation in 23S rRNA gene. The proportion of isolates harboring this mutation increased significantly after 2022 and dominated by 2024. All tested isolates displayed low MICs to alternative agents: trimethoprim/sulfamethoxazole (MICs ≤ 0.5/9.5 mg/L), cefoperazone/sulbactam (MICs ≤ 0.064/0.032 mg/L), and piperacillin/tazobactam (MICs ≤ 0.064/4 mg/L). Notably, macrolide-resistant isolates harboring ptxA1-ptxP3-prn150 genotype formed a distinct sub-clone within the ptxP3 clade.
conclusionsOur findings demonstrate the current dominance of macrolide-resistant B. pertussis strain harboring ptxP3 and prn150 in Guangzhou since 2024. This study provides epidemiological and microbiological insights to guide local pertussis control strategies and to offer antimicrobial resistance monitoring efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.